- Conditions
- Hemophilia
- Interventions
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 8
- States / cities
- Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–180
of 180
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia A
- Interventions
- Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- Hemophilia A
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
- Conditions
- Severe Hemophilia A
- Interventions
- rFVIIIFc
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sacramento, California • Waltham, Massachusetts + 2 more
- Conditions
- Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
- Interventions
- Coagulation FVIIa (Recombinant)
- Biological
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas
- Conditions
- Von Willebrand Diseases
- Interventions
- Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid
- Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more
- Conditions
- Hemophilia A
- Interventions
- Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Hematologic Disease, Hemophilia A
- Interventions
- Kogenate (BAY14-2222)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 30 Years to 45 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chapel Hill, North Carolina • Houston, Texas
- Conditions
- Cardiovascular Disease
- Interventions
- FEIBA, Normal Saline
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hemophilia A
- Interventions
- PEGylated Recombinant Factor VIII, ITI
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more
- Conditions
- Hemophilia A
- Interventions
- Human-cl rhFVIII, Kogenate FS
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Sacramento, California • Denver, Colorado + 3 more
- Conditions
- Hemophilia A
- Interventions
- Antihemophilic factor, recombinant, manufactured protein-free
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 6 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more